February 1, 2011
TIDES is the only event that covers CMC manufacturing of peptide and oligo therapeutics in depth. It offers the largest showcase of providers of services and technology critical to the field and a proven track record of attendance that guarantees a superior networking opportunity. TIDES 2011 has four main content streams: Oligonucleotide and Peptide Manufacturing Technology and Product Development; Oligonucleotide Therapeutics Discovery; Peptide Discovery and Development; and Nucleic Acids Technologies for Molecular Diagnostics. Learn how to solve your CMC manufacturing, analytical, and regulatory challenges through the in-depth sessions.
Learn from your peers and other scientists involved in development of related molecules how to avoid pitfalls while adopting and using the latest technologies. Get behind-the-scenes insights into the industry’s most critical challenges in strategy discussion forums newly integrated into the program without conflicts with presentation times. Hear updates on the most important developments and cutting-edge science from the most forward-thinking luminaries in Monday’s keynote and plenary sessions. Sharpen your skills with new preconference courses. Update your knowledge on therapeutics nearing commercialization with up-to-the-minute reports on Isis/Genzyme’s Mipomersen antisense drug, phosphoro-diamidate morpholino oligos, GSK2402968 (Prosensa [PRO-051]) and GS-101 (Aganirsen).
Popular content on oligonucleotide therapeutics discovery added in 2010 returns for 2011. Explore insights into trafficking mechanisms to improve oligonucleotide delivery and distribution. Learn about creative chemical modification and design approaches to improve drug-like properties in your molecules. Hear new data, challenges, and lessons learned from molecules in preclinical and clinical studies to help guide your R&D. Find strategies to accelerate discovery and development in all classes of oligonucleotide molecules: siRNA, antisense, LNA, aptamer, miRNA, and immune modulation.
Preconference Courses
Full-Day Course: ”Manufacturing and Analysis of Oligonucleotides: Moving Through the Phases of Clinical Development,” led by G. Susan Srivatsa (president of ElixinPharma) and Fran Wincott (president of Wincott and Associates Inc.)
Half-Day Courses: “Regulatory Strategies for Peptides,” led by Duu-Gong Wu (executive director of the Consulting Division at PharmaNet, Inc.) and Blair A. Fraser (senior consultant at Biologics Consulting Group)
“Practical Applications of Mass Spectrometry for Quality Control,” led by Claus Rentel (director of analytical development and quality control at Isis Pharmaceuticals, Inc.)
New This Year
The new format includes two full days on CMC issues: Tuesday for standard molecules and Wednesday for complex molecules and those in delivery vehicles, with each presentation giving experience with manufacturing, analytical and regulatory aspects.
Peptide Discovery and Development: Peptides Coming of Age as Intracellular Drugs, Delivery Agents, and Modulators of Previously “Undruggable” Targets and Disease Mechanisms
Hear breaking data on three cell-permeable peptides as drugs and find strategies for modulating intracellular and previously “undruggable targets”
Discover how peptides can be used as starting points to create novel scaffolds, as vectors/ligands for targeting specific cell types, or as protein–protein interaction modulators.
Evaluate creative technologies and techniques for peptide discovery, selection and design to accelerate your lead discovery efforts.
Find new ways to get peptides into cells, exploit uptake mechanisms, and enable peptide-mediated delivery of oligos, proteins, or other cargoes.
Keynote Addresses
“Causes and Consequences of microRNA Dysregulation in Cancer,” by Carlo M. Croce (John W. Wolfe Chair in human cancer genetics; professor/chair of the Department of Molecular Virology, Immunology, and Medical Genetics; and director of the Institute of Genetics at the Ohio State University Medical Center)
Plenary Sessions: “Peptide Ligation in the Development of Therapeutics,” by Stephen B.H. Kent (professor of chemistry, biochemistry and molecular biology at the University of Chicago)
“Receptor Mediated Delivery of Oligonucleotide Conjugates,” by Rudy Juliano (professor in the division of molecular pharmaceutics at the Eshelman School of Pharmacy, University of North Carolina at Chapel Hill)
“Protein Ligation: An Enabling Technology for Studying Protein Post-Translational Modifications,” by Tom W. Muir (professor in the laboratory of synthetic protein chemistry at Rockefeller University).
You May Also Like
